上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。
Alflutinib mesylate (Synonyms: 甲磺酸伏美替尼; Furmonertinib mesylate; AST2818 mesylate) 纯度: 98.16%
Alflutinib (Furmonertinib) mesylate 是一种有效的 EGFR 抑制剂。Alflutinib (Furmonertinib) mesylate 抑制 EGFR 活性突变以及 T790M 获得性耐药突变。Alflutinib (Furmonertinib) mesylate 具有研究癌症疾病的潜力,尤其是非小细胞肺癌 (NSCLC)。
Alflutinib mesylate Chemical Structure
CAS No. : 2130958-55-1
规格 | 价格 | 是否有货 | 数量 |
---|---|---|---|
5 mg | ¥2000 | In-stock | |
10 mg | ¥3000 | In-stock | |
50 mg | ¥8500 | In-stock | |
100 mg | ¥12500 | In-stock | |
200 mg | 询价 | ||
500 mg | 询价 |
* Please select Quantity before adding items.
Alflutinib mesylate 相关产品
•相关化合物库:
- Drug Repurposing Compound Library Plus
- Clinical Compound Library Plus
- Bioactive Compound Library Plus
生物活性 |
Alflutinib (Furmonertinib) mesylate is is a potent inhibitor of EGFR. Alflutinib (Furmonertinib) mesylate inhibits EGFR active mutations as well as the T790M acquired resistant mutation. Alflutinib (Furmonertinib) mesylate has the potential for the research of cancer diseases, especially non-small cell lung cancer (NSCLC)[1]. |
||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
IC50 & Target[1] |
|
||||||||||||||||
体外研究 (In Vitro) |
Alflutinib (Furmonertinib) mesylate is designed to inhibit EGFR active mutations as well as the T790M acquired resistant mutation[1]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only. |
||||||||||||||||
Clinical Trial |
|
||||||||||||||||
分子量 |
664.70 |
||||||||||||||||
Formula |
C29H35F3N8O5S |
||||||||||||||||
CAS 号 |
2130958-55-1 |
||||||||||||||||
中文名称 |
甲磺酸伏美替尼;甲磺酸艾氟替尼 |
||||||||||||||||
运输条件 |
Room temperature in continental US; may vary elsewhere. |
||||||||||||||||
储存方式 |
4°C, sealed storage, away from moisture *该产品在溶液状态不稳定,建议您现用现配,即刻使用。 |
||||||||||||||||
溶解性数据 |
In Vitro:
DMSO : 5 mg/mL (7.52 mM; Need ultrasonic) 配制储备液
*
请根据产品在不同溶剂中的溶解度,选择合适的溶剂配制储备液;该产品在溶液状态不稳定,建议您现用现配,即刻使用。 In Vivo:
请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
|
||||||||||||||||
参考文献 |
|
所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务